Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug
Bristol-Myers Squibb and 2seventy bio shares dropped after the FDA said it would not make a decision on expanded use of the companies' cancer drug next month.
( 1
min )